WESTLAKE VILLAGE, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it has enrolled the first patient in Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of janus kinase type 1 (JAK1), in adult patients with chronic hand eczema.
News Ticker
- [ June 10, 2023 ] Graduating senior lights the path for transfer students – through her award-winning research and mentoring Los Angeles Biotech News
- [ June 10, 2023 ] Postdoctoral Scientist – Karsh Division of Gastroenterology and Hepatology – Part-Time – CEDARS-SINAI – Los Angeles, CA Los Angeles Biotech Jobs
- [ June 10, 2023 ] Adcomm votes yes on Leqembi full OK; Merck brings first IRA lawsuit; Special: LGBTQ+ leaders; Best-paying biopharma jobs; and more Los Angeles Biotech News
- [ June 10, 2023 ] Scientist, Cell Biology – Thermo Fisher Scientific – West Hills, CA Los Angeles Biotech Jobs
- [ June 10, 2023 ] Security Officer – Biotechnology Company – Allied Universal® – Oceanside, CA Los Angeles Biotech Jobs
Copyright © 2021 Biotech Networks, LLC
